Identifying the Components of Acidosis in Patients With Severe Plasmodium falciparum Malaria Using Metabolomics

Stije J. Leopold,1,2 Aniruddha Ghose,3 Erik L. Allman,4 Hugh W. F. Kingston,12 Amir Hossain,3 Asok Kumar Dutta,3 Katherine Plewes,1,2 Kesinee Chotivanich,1 Nicholas P. J. Day,12 Joel Tarning,12 Markus Winterberg,12 Nicholas J. White,12 Manuel Linñas,12 and Arjen M. Dondorp1,2

1Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom; 3Department of Internal Medicine, Chittagong Medical College Hospital, Bangladesh; and 4Department of Biochemistry and Molecular Biology and Huck Center for Malaria Research, and 5Department of Chemistry, Pennsylvania State University, State College, PA

Background. Acidosis in severe Plasmodium falciparum malaria is associated with high mortality, yet the pathogenesis remains incompletely understood. The aim of this study was to determine the nature and source of metabolic acids contributing to acidosis in patients with severe falciparum malaria.

Methods. A prospective observational study was conducted to characterize circulating acids in adults with P. falciparum malaria (n = 107) and healthy controls (n = 45) from Bangladesh using high-resolution liquid chromatography–mass spectrometry metabolomics. Additional in vitro P. falciparum culture studies were performed to determine if parasites release the acids detected in plasma from patients with severe malaria acidosis.

Results. We identified previously unmeasured plasma acids strongly associated with acidosis in severe malaria. Metabolic analysis of P. falciparum parasites in vitro showed no evidence that these acids are released by the parasite during its life cycle. Instead, 10 of the plasma acids could be mapped to a gut microbial origin. Patients with malaria had low L-citrulline levels, a plasma marker indicating reduced gut barrier integrity. Longitudinal data showed the clearance of these newly identified acids was delayed in fatal cases.

Conclusions. These data suggest that a compromise in intestinal barrier function may contribute significantly to the pathogenesis of life-threatening acidosis in severe falciparum malaria.

Clinical Trials Registration. NCT02451904.

Keywords. severe malaria; Plasmodium falciparum; metabolic acidosis; metabolomics; gut-barrier integrity.

Severe malaria remains an important cause of premature death in malaria-endemic countries with 435 000 deaths ascribed to malaria infections in 2017, mostly in sub-Saharan Africa [1]. The vast burden of severe malaria is caused by the Plasmodium falciparum parasite. Early diagnosis and treatment with parenteral artesunate reduces mortality, but case fatality rates still range between 10% and 30% depending on the extent of vital organ dysfunction [2]. Adjunctive therapies might close this case fatality gap if they target pivotal pathophysiological pathways, but this requires a further understanding of the pathophysiology of severe malaria. To date, the only adjunctive interventions shown to reduce severe malaria mortality are renal replacement therapies in acute renal failure. All others have failed.

Unrestrained asexual replication of P. falciparum during the blood stage of malaria infection leads to coma, renal failure, and metabolic acidosis [3]. The key pathogenic mechanism in severe falciparum malaria is sequestration of infected red blood cells in the microcirculation of vital organs [4]. This is mediated by parasite-derived ligands, mainly P/EMP1, and a range of host endothelial cell surface receptors, including CD36, EPCR, and ICAM1 [5]. Microvascular sequestration contributes to endothelial dysfunction, capillary and venular blockage, and subsequent organ failure [6]. Histopathology studies have shown preferential sequestration of infected erythrocytes in the brain and intestines [7, 8].

Metabolic acidosis is one of the strongest predictors of mortality in both pediatric and adult cases of severe malaria [6, 9–11]. Acidosis is harmful in itself as it dysregulates cellular metabolism [12]. In severe malaria, acidosis is also a marker of tissue dysoxia, mainly caused by anaerobic production of L-lactate [13]. Depending on the malaria parasite biomass, parasite-derived anaerobic metabolism of glucose to lactate also
METHODS

Ethical Considerations

The clinical study protocol was reviewed and approved by the local ethics review board; the Chittagong Medical College Ethics Committee, Bangladesh; and the Oxford Tropical Research Ethics Committee, United Kingdom. The trial was registered at ClinicalTrials.gov (identifier NCT02451904). All participants provided informed written consent after the nature and possible consequences of the studies were explained. If patients were clinically too unwell to provide consent themselves, their attending relatives provided informed written consent.

Study Design

A prospective observational study was conducted in Chittagong Medical College Hospital, Bangladesh. Chittagong Medical College Hospital is a large government tertiary referral hospital with approximately 1300 beds, serving an urban population of approximately 5 million people. At the time of the study, the hospital had 3 internal medicine wards with a bed occupancy rate regularly reaching >150%. Hemodialysis was available in a separate renal unit operating 8 hemofiltration machines. The hospital has an intensive care unit with 12 beds of which 7 were equipped with mechanical ventilators at the time of the study.

Male and female adults (>12 years) with a blood slide positive for asexual blood stages of *P. falciparum* (including mixed infection with nonfalciparum species) were recruited between 2014 and 2015. Severe and uncomplicated falciparum malaria was defined according to the World Health Organization (WHO) criteria for severe malaria [16], modified by Hien et al [17]. Severe acidosis was defined according to WHO criteria [16]. Acute kidney injury was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria (www.kdigo.org).

At enrollment we took a medical history, assessed vital signs, performed a physical examination, and drew blood samples for blood gas analysis, measurement of PfHRP2, and metabolic analysis of plasma. During hospitalization, we performed follow-up every 6 hours with vital signs to assess clinical recovery and blood sampling to assess asexual parasite clearance. Patients were treated with standard doses of intravenous artesunate followed by a full course of artemether-lumefantrine [16] and were followed until hospital discharge.

Sample Size

The effect size of individual metabolites between study groups was unknown a priori, and no pilot studies had been done before. Consecutive patients with malaria were enrolled. We aimed to include patients with different levels of disease severity to observe a wide range of natural variation in the degree of acidosis.

Plasma Samples for Metabolomics

Blood for metabolomic analysis was drawn from a fresh in-dwelling catheter in the forearm, collected in lithium-heparin tubes, centrifuged immediately, and flash-frozen in liquid nitrogen. Serial plasma samples were extracted in duplicate using a solid-phase extraction technique [18] and by protein precipitation using methanol [19]. Analysis sequences were prepared by regularly interspersing quality control samples (1:10) for post hoc quality control robust locally estimated scatterplot smoothing (LOESS) signal correction [20].

*Plasmodium falciparum* 3D7 Cultures

*Plasmodium falciparum* 3D7 (PF3D7) strain parasites were cultured and maintained using standard methods [21]. The cultures were synchronized twice using 5% sorbitol using standard procedures with an interval of 6 hours immediately before media sampling. Cultures maintained at 2% hematocrit were split across 3 flasks to achieve parasitemias of 1%, 2%, and 3%. An uninfected red cell control was prepared at 2% hematocrit with blood from the same donor. Media in all flasks were replenished 1 hour prior to the first sampling time point, and were not refreshed afterwards. Duplicate media samples were collected from all flasks at 5 time points across the life cycle, to include a small ring stage (12 hours), large ring stage (20 hours), trophozoite stage (32 hours), schizont stage (40 hours), and schizogony stage (52 hours). At each time point, parasitemia was assessed by microscopy, and cell counts were done using a hemocytometer.

Mass Spectrometry Measurement, Spectral Data Processing, and Annotation

Ultra-high performance liquid chromatography Orbitrap mass spectrometry (LC-MS) was performed using a C18 column (Hydro-RP, Phenomenex) with tributylamine as an ion-pairing agent, analyzed over a 25-minute run-time protocol in negative ion mode, covering an m/z range of 70–1000 Da on a Thermo Exactive Plus Orbitrap (ThermoFisher) [22] (Supplementary Materials). Base peak chromatograms are shown in Supplementary Figures 2–4. Following peak selection and rigorous quality control, peak annotation was carried out using an in-house library of 292 chemically confirmed metabolic...
intermediates from major human and *P. falciparum* metabolic pathways. Unidentified peaks were putatively annotated using Human Metabolome Database (HMDB; version 4.0) datasets [23] with confidence at an m/z tolerance of 10 ppm. We filtered the final dataset down to only include acids (based on selection of pKa < 7.0). The metabolomic data analysis pipeline is shown in a flow diagram (Supplementary Figure 1).

**Measures of Intestinal Integrity**

We performed an independent LC-MS assay to quantify the plasma levels of L-citrulline and L-arginine. L-citrulline is a nonproteino- genetic amino acid produced in enterocytes (predominantly) from plasma glutamine and it is an important substrate for plasma L-arginine [24]. Loss of enterocyte mass reduces splanchnic L-citrulline metabolism [25]. Lowered plasma L-citrulline has been associated with increased gut permeability and endotoxemia [26].

### Table 1. Baseline Characteristics in the Study Groups

| Characteristic            | Severe Malaria (n = 60) | Uncomplicated Malaria (n = 47) | Healthy Controls (n = 45) | P Value |
|---------------------------|-------------------------|-------------------------------|--------------------------|---------|
| Age, y                    | 28 (22–40)              | 30 (22–45)                    | 29 (23–35)               | .831    |
| Female sex, No. (%)       | 21 (35)                 | 13 (28)                       | 16 (36)                  | .654    |
| BMI, kg/m²                | 21 (20–24)              | 22 (19–24)                    | 24 (21–27)               | .001    |
| Mortality, No (%)         | 20 (33)                 | 0                             | 0                        | .001    |
| Clinical examination      |                         |                               |                          |         |
| Temperature, °C           | 38 (37–39)              | 37 (37–38)                    | 36 (36–37)               | < .001  |
| Coma depth               | 10 (8–14)               | 15 (15–15)                    | 15 (15–15)               | < .001  |
| Pulse rate, per minute    | 110 (99–130)            | 98 (89–112)                   | 83 (78–91)               | < .001  |
| Respiratory rate, per minute | 36 (28–44)          | 24 (23–29)                    | 18 (16–20)               | < .001  |
| Mean arterial pressure, mm Hg | 82 (72–88)       | 79 (73–87)                    | 93 (87–100)              | < .001  |
| Laboratory assessments    |                         |                               |                          |         |
| Parasitemia, parasites/µL³ | 44.868 (24.406–62.483) | 3840 (1723–8558)              | 0                        | < .001  |
| PHPR2, ng/dL³             | 4356 (3218–5896)        | 674 (429–977)                 | 0                        | < .001  |
| Glucose, mmol/L           | 6.7 (5.8–8.7)           | 6.7 (5.8–7.8)                 | 5.9 (5.2–6.7)            | .216    |
| Sodium, mmol/L            | 135 (131–138)           | 134 (132–137)                 | 140 (139–141)            | < .001  |
| Potassium, mmol/L         | 4 (3.6–4.3)             | 3.4 (3.2–3.7)                 | 3.6 (3.5–3.8)            | < .001  |
| Chloride, mmol/L          | 105 (101–108)           | 104 (99–107)                  | 103 (102–106)            | .153    |
| Phosphate, mEq/L          | 3.2 (2.5–3.4)           | 2.7 (2.1–3.4)                 | 3.7 (3.3–4.2)            | < .001  |
| Magnesium, mmol/L         | 2.7 (2.3–3.2)           | 2.3 (2.1–2.5)                 | 2.8 (2.6–2.9)            | < .001  |
| Calcium (ionized), mmol/L | 0.9 (0.9–1)             | 1 (0.9–1.1)                   | 1.1 (1–1.2)              | < .001  |
| Creatinine, mmol/L        | 132 (86–361)            | 92 (69–102)                   | 71 (57–78)               | < .001  |
| Blood urea nitrogen, mmol/L | 41 (26–86)            | 16 (11–25)                    | 7 (5–10)                 | < .001  |
| Albumin, g/L              | 27 (24–30)              | 30 (26–35)                    | 45 (43–49)               | < .001  |
| Hemoglobin, g/L           | 90 (64–109)             | 97 (80–110)                   | 135 (120–149)            | < .001  |
| White blood cells, ×10³/µL | 9.3 (7.15–13.3)       | 6.1 (5.2–7.9)                 | 7.9 (6.8–9.1)            | < .001  |
| Platelets, ×10³/µL        | 27 (17–43)              | 46 (37–95)                    | 233.5 (178.5–277)        | < .001  |
| pH                        | 7.38 (7.33–7.43)        | 7.43 (7.4–7.46)               | 7.37 (7.35–7.39)         | < .001  |
| PaCO₂, mm Hg              | 29 (25–34)              | 34 (31–36)                    | 46 (43–52)               | < .001  |
| HCO₃⁻, mmol/L             | 178 (14.7–19.8)         | 213 (19.1–23.9)               | 25.6 (22.4–27.6)         | < .001  |
| Plasma SBDc, mmol/L⁵       | 6.6 (4.5–9.7)           | 2.5 (0.2–5)                   | −1 (−2.9 to 0.3)         | < .001  |
| SiDAs, mEq/L              | 41 (38.2–44.3)          | 40.2 (38.9–42.3)              | 46.1 (43–48.3)           | < .001  |
| SiDe, mEq/L               | 25 (22.4–27)            | 28.7 (25.8–30.5)              | 35.1 (33–36.5)           | < .001  |
| Strong ion gap, mEq/L      | 15.8 (13.3–19.5)        | 12.1 (10.8–14.3)              | 10.4 (8.6–12)            | < .001  |
| Anion gap, mmol/L²        | 12.3 (10.3–14.6)        | 9.3 (6.9–11.2)                | 7 (5.6–8.4)              | < .001  |
| L-lactate, mmol/L         | 3.6 (2.2–4.9)           | 1.6 (1.2–1.8)                 | 1.2 (1–1.4)              | < .001  |

Data are presented as median (interquartile range) unless otherwise indicated.

Abbreviations: BMI, body mass index; HCO₃⁻, bicarbonate; PaCO₂, partial pressure of carbon dioxide; PHPR2, plasma *Plasmodium falciparum* histidine-rich protein 2; SBDc, standard base deficit; SiDAs, apparent strong ion difference; SiDe, effective strong ion difference.

²Depth of coma was assessed by the Glasgow Coma Scale (3–15).

³Geometric mean (95% geometric confidence interval).

⁴Corrected for plasma albumin and phosphate concentrations.
using a significance analysis of microarrays (SAM) regression analysis tool ('samr' package, R) which allowed the calculation of local false detection rate (FDR) and q value [27]. Metabolites were selected if regression showed an FDR ≤ .15 and q ≤ .001. Log2 (fold change) was calculated for individual metabolites and visualized in a heat map for patients with severe malaria, stratified by the degree of acidosis. Spearman correlation coefficients were calculated for assessing correlations. Mann–Whitney U and Kruskal–Wallis tests were used for comparing nonnormally distributed variables.

RESULTS

In total, 152 patients were recruited in this study: 60 with severe malaria of whom 20 (33%) died, 47 with uncomplicated falciparum malaria, and 45 healthy local controls. Baseline characteristics are shown in Table 1. There were no significant differences between the study groups in age (P = .83, Kruskal–Wallis test) or sex (P = .67, Kruskal–Wallis test); the majority of the study participants were young males (Table 1).

Acidosis in Severe Malaria Is Associated With Unmeasured Anions

Acid-base status was assessed by blood gas analysis and estimation of the unmeasured acid load in all participants at enrollment (Supplementary Methods). The majority of patients with severe falciparum malaria had metabolic acidosis. Severe acidosis, defined as a standard base deficit corrected for albumin (SBDc) >8 mmol/L [16], was present in 23 of 60 (38%) severe malaria cases, and moderate acidosis (SBDc >3.3 and ≤ 8 mmol/L) was found in 28 (47%) cases. Only 9 (15%) severe malaria cases had mild or no acidosis, defined as a standard base deficit corrected for albumin SBDc ≤ 3.3 mmol/L [28].

The case fatality rate among patients with severe malaria increased stepwise with the degree of acidosis, from 10% in mild acidosis, 21% in moderate acidosis, to 56% in severe acidosis. SBDc was elevated significantly in fatal cases (10.9 mmol/L; standard deviation [SD], 5.1) compared with survivors (6.0 mmol/L; SD, 3.3; P = .0004) (Figure 1A). The proportion of acidosis explained by L-lactate decreased with increasing severity of acidosis: L-lactate explained on average 89% (SD, 19%) of SBDc in patients with mild or no acidosis, 61% (SD, 28%) in moderate acidosis, and 47% (SD, 24%) in severe acidosis (Figure 1B).

Further evidence for a prognostic unmeasured acid load was found by estimation of the anion gap (AGc) and the strong ion gap (SIG), both of which were elevated significantly in patients who died (Figure 1C and 1D). SBDc and other estimates of unidentified acids were strongly correlated including AGc (Spearman r = 0.61; P < .0001) and

![Figure 1](https://academic.oup.com/jid/article-abstract/219/11/1766/5253254)
SIG (Spearman $r = 0.46; P < .0001$). As expected, there was also a correlation between SBDc and creatinine (Spearman $r = 0.43; P < .0001$). Acute kidney injury was present in 19 of 51 (37%) patients with acidosis, so the majority of patients with acidosis did not have evidence of renal impairment.

**High-Resolution Metabolomics Reveals Differentially Abundant Metabolites**

To characterize contributing organic acids, we analyzed plasma samples of all 152 participants in duplicate using an ultra-high-performance LC-MS (UHPLC-MS) platform. This analytical platform detected 1355 metabolic features in plasma of study participants in a mass-to-charge ratio (m/z) range of 70–1000 Da. The final data contained 86 acids identified using an in-house chemical reference library; if chemical standards were unavailable, metabolites were putatively annotated using HMDB, version 4.0 ([http://www.hmdb.ca/](http://www.hmdb.ca/)) (Supplementary Figure 5).

Sources of variation between the patient samples were explored by PCA, which showed a clear separation according to study group on PC1 (Supplementary Figure 6A). Differences between study groups were investigated by differential metabolite abundance analysis, and 23 metabolites were found to be significantly elevated in patients with uncomplicated malaria when compared to healthy controls ($\log_2$ [fold change] >1, Benjamini-Hochberg adjusted

**Figure 2.** Metabolomic analysis of plasma of patients with severe malaria. A, Heat map of all organic acids that were significantly associated with the standard base deficit corrected for albumin and phosphate (false discovery rate < 0.15). Visualization was done by calculating the $\log_2$ (fold change) normalized against the levels found in healthy controls (HE). B, Venn diagram of microbial acids implicated in acidosis. Diaminopimelic acid is a component of gram-negative cell walls; p-hydroxyphenylacetic acid is a product of polyphenol metabolism by gut microbiota; piperic acid is a product of lysine metabolism in intestinal bacteria. * = <0.05; **** = <0.0001. Abbreviations: DAP, diaminopimelic acid; HE, healthy controls; HPAA, hydroxyphenylacetic acid; ns, not significant; P. falciparum HRP2, plasma Plasmodium falciparum histidine-rich protein 2; SBDc, standard base deficit corrected for albumin and phosphate; SM, severe malaria; UM, uncomplicated malaria.
metabolites were significantly increased in patients with severe malaria compared to uncomplicated malaria (log, [fold change] >1), Benjamini–Hochberg adjusted \( P < .01 \) (Supplementary Figure 6B). Furthermore, a total of 26 metabolites were significantly increased in patients with severe malaria compared to healthy controls (Supplementary Figure 7). Acetaminophen glucuronide is a water-soluble acidic metabolite from hepatic glucuronidation of acetaminophen (paracetamol), showing (unsurprisingly) that patients with malaria were taking antipyretics.

A major difference was also observed in the levels of acetaminophen glucuronide in the plasma from patients who had malaria compared to healthy controls (Supplementary Figure 7). Acetaminophen glucuronide is a known component of the cell wall of gram-negative intestinal bacteria [33]. A set of 3 phenyl compounds, including p-hydroxyphenylacetic acid, phenyllactic acid, and hydroxyphenyllactic acid, are known intermediates of phenylalanine metabolism in intestinal bacteria [34]. Indoxyl sulfate has been described to derive from bacterial metabolism [31]. The increase in acids potentially derived from an enteric source suggests a role for translocation from the gut, compounded by renal impairment if these acids undergo renal clearance.

### Table 2. Gut Microbial Acids Implicated in Severe Malaria Acidosis

| Name                          | HMDB ID          | Log2 (FC)a | pKa  | Biological Role/Pathway                                  | Related Bacteria                        | Reference |
|-------------------------------|------------------|------------|------|--------------------------------------------------------|----------------------------------------|-----------|
| Dimethylglycine               | HMDB0000092      | 3.4        | 1.88 | Glycine metabolism                                     | Bifidobacterium spp                    | [32]      |
| Diaminopimelic acid           | HMDB0001370      | 3          | ...  | Gram-negative cell wall component                      | Gram-negative bacteria                  | [33]      |
| Hydroxyphenylacetic acid      | HMDB00020        | 2.8        | 4    | Phenylalanine metabolism                               | Clostridium spp. Bifidobacterium spp.  | [32]      |
| Hydroxyphenylactic acid       | HMDB000755       | 2.7        | 3.58 | Phenylalanine metabolism                               | Clostridium spp. Bifidobacterium spp.  | [35]      |
| Phenyllactic acid             | HMDB000779       | 2.5        | 4.02 | Phenylalanine metabolism                               | Clostridium spp. Lactobacillus spp.    | [36]      |
| 5-aminopentanoic acid         | HMDB0003355      | 1.4        | 4.65 | Protein synthesis, amino acid biosynthesis             | Firmicutes spp                         | [37]      |
| Picrocic acid                 | HMDB0000070      | 3.6        | 2.06 | Protein synthesis, amino acid biosynthesis             | Escherichia coli                       | [38]      |
| Hippuric acid                 | HMDB000714       | 4.1        | 3.6  | Benzoate metabolism                                    | Clostridium spp                        | [31]      |
| Indoxyl sulfate               | HMDB000662       | 3.7        | –1.82| Uremic toxin                                           | Clostridium sporogenes E. coli         | [32]      |

Gut microbial acids associated with acidosis among patients with severe malaria. Abbreviations: FC, fold change; HMDB, Human Metabolome Database; pKa, acid dissociation constant.

aIdentity confirmed by chemical standards, otherwise annotated using HMDB, version 4.0.
bLog, (fold change) compared to uncomplicated malaria controls as a clinically relevant reference group.

As stated or predicted in HMDB, version 4.0.
we performed an in vitro culture study using *P. falciparum* 3D7 strain parasites. A metabolomic analysis was conducted of temporal changes of metabolites in the spent culture media of P3D7 and nonparasitized red blood cell controls throughout the parasite life cycle. Culture media metabolites were extracted using the same methanol extraction techniques applied to patient plasma, and the samples were analyzed using the same UHPLC-MS platform (Supplementary Figure 4).

As expected [35], the release of metabolites from infected red blood cells increased during the trophozoite stage of asexual intraerythrocytic development and peaked after schizogony (Figure 3A). We detected 11 of 36 metabolic acids associated with clinical acidosis in the media of P3D7 cultures. Except for lactate (parasites produce both D and L forms), none of these acids showed a cumulative increase during the parasite life cycle (Figure 4B). A minor increase was observed following schizogony (52 hours postinfection), indicating the release of red
cell parasitized red blood cells (Figure 3B). We did observe an increase in the levels of metabolites related to glycolysis, including pyruvate and lactate (Figure 3C), reflecting the high rates of glycolysis in parasitized red cells [14, 35]. In conclusion, we found no evidence to suggest that *P. falciparum* parasites release any of the microbial acids contributing to acidosis in severe malaria patients.

**Markers Intestinal Barrier Dysfunction in Patients With Malaria**

If intestinal leakage is driving the translocation of microbial acids into the circulation, we expected to find markers of reduced gut barrier integrity in patients with malaria compared to healthy controls. To test this hypothesis, we quantified plasma concentrations of L-arginine and L-citrulline and found a significant reduction in L-arginine and L-citrulline levels in patients with *P. falciparum* malaria (*P* < .0001) (Figure 4) [36]. However, reduced intestinal L-citrulline appearance in patients with malaria may also contribute to the low plasma L-arginine levels. We conclude that decreased L-citrulline levels observed in patients with *P. falciparum* malaria are indicative of intestinal barrier dysfunction and are associated with low plasma L-arginine.

**Fatal Cases of Severe Malaria Show Delayed Plasma Clearance of Newly Identified Acids**

We analyzed the temporal profiles of plasma levels of gut microbial acids during the first 48 hours of hospitalization (Figure 5: the full group of 10 microbial acids is shown in Supplementary Figure 9). All gut microbial acids were elevated in fatal cases and showed a delayed clearance over time in patients with a fatal course, suggesting prognostic relevance. A multivariate logistic regression model including major determinants of outcome in severe malaria showed that besides depth of coma and L-lactate, diaminopimelic acid concentrations were also an independent predictor of outcome (Supplementary Table 1).

**DISCUSSION**

In this study, we characterized circulating acids in patients with severe falciparum malaria. LC-MS–based metabolomics revealed elevated levels of acids, which are known to be produced by gut bacteria. Assaying spent medium of *P. falciparum* in vitro cultures at different stages of asexual development did not identify *P. falciparum* as a likely source for these newly identified acids. Patients with malaria had markers indicative of loss of gut barrier dysfunction. Clearance of microbial acids was delayed in fatal cases, supporting their prognostic significance in adult patients with severe malaria. Combined, these findings point toward a potential role for translocation of bacterial acids from the gut into the bloodstream, suggesting a novel pathogenesis for acidosis, contributing to disease severity and poor prognosis in patients with severe *P. falciparum* malaria.

Severe falciparum malaria predisposes to concomitant bacteremia [37], often with enteric bacteria. Increased intestinal permeability in patients with severe malaria has been shown by sugar absorption tests [38, 39]. Endotoxemia, likely arising from translocation of intestinal bacteria or bacterial products, and perhaps compounded by reduced hepatic clearance, has been found in children and adults with severe malaria [40, 41]. The mechanisms underlying intestinal barrier dysfunction in severe malaria are probably related to sequestration of infected red cells in the splanchnic microcirculation [7, 8]. The gut is a favored site for sequestration, and mechanical obstruction in gut capillaries has been visualized in vivo. Reduced gut microcirculatory flow may cause local intestinal ischemia [42]. One proposed model to explain increased intestinal permeability is that of parasite-induced histamine release in the gut wall, leading to loss of enterocyte tight junctions [43]. We found that plasma concentrations of PfHRP2 correlated positively with the newly identified organic acids, suggesting that an increased parasite biomass and subsequent sequestration was associated with translocation of microbial acids (Supplementary Figure 10). Alternative explanations for translocation of microbial acids may include diffuse

![Figure 4](https://academic.oup.com/jid/article-abstract/219/11/1766/5253254)
Splanchnic ischemia due to severe hemodynamic shock [44], sepsis [45], or coinfection with invasive enteric pathogens [46]. Further studies are needed to investigate the exact pathogenic mechanisms of increased intestinal permeability during severe malaria. Whether organic acids from an enteric bacterial source also accumulate during other disease states or in critically ill patients with a leaky gut warrants prospective investigation.

In the presence of a compromised intestinal barrier, the composition of the gut microbiota may play a role in the pathogenesis of severe malaria acidosis. Recent mouse studies have found that the severity of malaria was affected by the composition of the gut microbiota [47]. Increased intestinal permeability during malaria infection may coincide with changes in the composition of the gut microbiota [48]; however, this has not been investigated in humans.

Our findings suggest an interaction between the human host, the *Plasmodium falciparum* parasite, and the gut microbiota. We postulate that sequestration of parasitized red cells in the splanchnic microcirculation may cause intestinal barrier dysfunction, predisposing patients to translocation of gut microbial acids and enteric bacteria (Supplementary Figure 11). If increased plasma concentrations of bacterial acids signify a loss of gut barrier function, this could be predictive for concomitant gut-derived bacteremia. Unfortunately, quality-controlled blood culture facilities were unavailable at the study site.

It should be noted that although L-citrulline is considered a marker of gut integrity, the observed reduction of L-citrulline in patients with malaria can be compounded by significant scavenging by *P. falciparum* parasites [35]. Additionally, it is possible that long-term storage may also affect the stability of low-molecular-weight molecules, including organic acids and L-citrulline [49]. We do not expect sample degradation as storage time was kept to a minimum and there were clear and significant metabolic differences between patient groups.

**Plasmodium falciparum** clone 3D7 was selected for the in vitro studies because it is very well characterized, grows efficiently in vitro, and has been fully sequenced and well annotated, and the 3D7 intraerythrocytic developmental cycle transcriptome is available [50]. While our analysis is limited to the investigation of this single strain, which might have undergone physiological changes following long-term laboratory adaptation, future studies should seek to include clinical isolates to compare parasite acid production using parasites isolated from patients with or without acidosis. Unfortunately, in the current study, this was not possible.

In conclusion, metabonomic profiling showed elevated plasma concentrations of gut microbial acids during severe malaria acidosis. Our data suggest a novel pathogenic pathway for acidosis in severe malaria, where loss of gut barrier function related to microcirculatory parasite sequestration may cause the translocation of microbial acids into the circulation.

**Supplementary Data**

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Author contributions.** A. M. D., S. J. L., and H. W. K. conceived the study. S. J. L., H. W. K., K. P., A. H., and A. K. D. provided patient care and sample collection. S. J. L., E. L. A., J. T., M. W., and M. L. designed and performed mass spectrometry experiments. S. J. L. and E. L. A. performed data analysis and made the figures. All authors read and approved the final manuscript.
Acknowledgments. We are grateful for all patients and their families who participated in the study. We thank Sanjib Kanti Paul and Sumon Sharma for their support with screening patients; Md Safiqul Mostafa Chowdhury for his administrative support; Marja Schilstra for data management; and Dr Phillip Smith and the Huck Institutes of the Life Sciences–Penn State Metabolomics Core Facility, for the use of mass spectrometry facilities.

Financial support. This work was supported by the Wellcome Trust (grant number 106698/B14/Z); a Nuffield Department of Medicine Prize Studentship of the University of Oxford (to S. J. L.); a Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease award (to M. L.); and a National Institutes of Health Ruth Kirschstein National Research Service Award individual postdoctoral fellowship (F32) (award number AI124507 to E. A.).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. World malaria report 2018. Geneva, Switzerland: WHO. 2018.
2. von Seidlein L, Olaosebikan R, Hendriksen ICE, et al. Predicting the clinical outcome of severe falciparum malaria in African children: findings from a large randomized trial. Clin Infect Dis 2012; 54:1080–90.
3. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151–7.
4. Marchiafava E, Bignami A. On summer-autumn malarial fevers. London: New Sydenham Society, 1894:1–232.
5. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of Plasmodium falciparum–infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med 2009; 11:e16.
6. Hanson J, Lam SWK, Mahanta KC, et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J Infect Dis 2012; 206:571–9.
7. Pongponratn E, Turner GDH, Day NPJ, et al. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69:345–59.
8. Seydel KB, Milner JR DA, Kamiza SB, Molynieux ME, Taylor TE. The distribution and intensity of parasite sequestration in comatose Malawian children. J Infect Dis 2006; 194:208–5.
9. Day NPJ, Phu NH, Mai NTH, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000; 28:1833–40.
10. Dondorp AM, Chau TTH, Nguyen HP, et al. Unidentified acids of strong prognostic significance in severe malaria. Crit Care Med 2004; 32:1683–8.
11. Jeeyapant A, Kingston HW, Plewes K, et al. Defining surrogate endpoints for clinical trials in severe falciparum malaria. PLoS One 2017; 12:1–15.
12. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010; 6:274–85.
13. Hanson J, Lee SJ, Hossain MA, et al. Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Med 2015; 13:122.
14. Elliott JL, Saliba KJ, Kirk K. Transport of lactate and pyruvate in the intraerythrocytic malaria parasite, Plasmodium falciparum. Biochem J 2001; 355(Pt 3):733–9.
15. Herdman MT, Srobeonvorakul N, Leopold SJ, et al. The role of previously unmeasured organic acids in the pathogenesis of severe malaria. Crit Care 2015; 19:317.
16. World Health Organization. Guidelines for the treatment of malaria. Geneva, Switzerland: WHO, 2015.
17. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artesether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76–83.
18. Srobeonvorakul N, Leepipatpiboon N, Dondorp AM, et al. Liquid chromatographic-mass spectrometric method for simultaneous determination of small organic acids potentially contributing to acidosis in severe falciparum malaria. J Chromatogr B Anal Technol Biomed Sci 2013; 941:116–22.
19. Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol 2012; 4:1–24.
20. Dunn WB, Broadhurst D, Begley P, et al; Human Serum Metabolome (HUSERMET) Consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011; 6:1060–83.
21. Trager W, Jensen J. Human malaria parasites in continuous culture. Science 1976; 193:673–5.
22. Lu W, Claquin MF, Melamud E, Amador-Noguez D, Caudy AA, Rabinowitz JD. Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer. Anal Chem 2010; 82:3212–21.
23. Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018; 46:D608–17.
24. Van Wijck K, Wijnands KAP, Meesters DM, et al. L-citrulline improves splanchnic perfusion and reduces gut injury during exercise. Med Sci Sports Exerc 2014; 46:2039–46.
25. Van De Poll MCG, Ligthart-melis GC, Boelens PG, et al. Citrulline and the gut. Intensive Care Med 2007; 80:741–4.
26. Grimaldi D, Guivarch E, Neveux N, et al. Markers of intestinal injury are associated with endotoxemia in successfully resuscitated patients. Resuscitation 2013; 84:60–5.
27. Li J, Tibshirani R. Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res 2013; 22:519–36.
28. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647–57.
29. English M, Marsh V, Amukoye E, Lowe B, Murphy S, Marsh K. Chronic salicylate poisoning and severe malaria. Lancet 1996; 347:1736–7.
30. Myall K, Sidney J, Marsh A. Mind the gap! An unusual metabolic acidosis. Lancet 2011; 377:526.
31. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci 2009; 106:3698–703.
32. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336:1262–7.
33. Goodell EW, Schwarz U. Release of cell wall peptides into culture medium by exponentially growing Escherichia coli. J Bacteriol 1985; 162:391–7.
34. Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med 2016; 8:46.
35. Olszewski KL, Morrisey JM, Wilinski D, et al. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe 2009; 5:191–9.
36. Yeo TW, Lampah DA, Gitawati R, et al. Impaired nitric oxide bioavailability and L-arginine–reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 2007; 204:2693–704.
37. Church J, Maitland K. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review. BMC Med 2014; 12:31.
38. Wilairatana P, Meddings JB, Ho M, Vannapani S, Looareesuwan S. Increased gastrointestinal permeability in patients with Plasmodium falciparum malaria. Clin Infect Dis 1997; 24:430–5.